YARW
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -3.51 | $97,000 | -$2M |
| 2026 Q1 | -209.50 | $86,000 | -$4M |
| 2025 Q4 | -250.00 | $130,000 | -$4M |
| 2025 Q3 | -425.00 | $169,000 | -$7M |
| 2025 Q2 | -325.00 | $69,000 | -$11M |
| 2025 Q1 | -500.00 | $202,000 | -$11M |
| 2024 Q4 | -700.00 | $84,000 | -$9M |
| 2024 Q3 | -725.00 | $121,000 | -$9M |